Xvivo Perfusion AB (publ) (XVIVO.ST)
SEK 465.0
(1.97%)
SEK 465.0
(1.97%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | 126.57 Million SEK | 6.15% |
| 2022 | 39.21 Million SEK | 66.54% |
| 2021 | 39.19 Million SEK | 330.94% |
| 2020 | -43.33 Million SEK | -155.72% |
| 2019 | 16.8 Million SEK | -11.74% |
| 2018 | 20.24 Million SEK | 53.52% |
| 2017 | 22.37 Million SEK | 37.96% |
| 2016 | 16.21 Million SEK | -14.76% |
| 2015 | 19.13 Million SEK | 64.53% |
| 2014 | 11.63 Million SEK | -5.08% |
| 2013 | 12.25 Million SEK | 5680.19% |
| 2012 | 799 Thousand SEK | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q1 | 18.99 Million SEK | -70.03% |
| 2024 Q2 | 43.64 Million SEK | 79.19% |
| 2024 Q3 | 20.47 Million SEK | -59.97% |
| 2023 Q4 | 4.5 Million SEK | -14.96% |
| 2023 Q3 | 5.3 Million SEK | 39.45% |
| 2023 Q1 | 11.2 Million SEK | -40.43% |
| 2023 Q2 | 3.8 Million SEK | -66.07% |
| 2023 FY | - SEK | 6.15% |
| 2022 Q1 | 4.62 Million SEK | -73.02% |
| 2022 FY | - SEK | 66.54% |
| 2022 Q4 | 18.81 Million SEK | 503.99% |
| 2022 Q3 | -4.65 Million SEK | -212.54% |
| 2022 Q2 | 4.13 Million SEK | -10.51% |
| 2021 Q2 | -9.35 Million SEK | -393.75% |
| 2021 Q4 | 17.13 Million SEK | 525.18% |
| 2021 Q3 | -4.03 Million SEK | 56.89% |
| 2021 FY | - SEK | 330.94% |
| 2021 Q1 | 3.18 Million SEK | 112.46% |
| 2020 FY | - SEK | -155.72% |
| 2020 Q2 | -8.21 Million SEK | -35800.0% |
| 2020 Q3 | -18.66 Million SEK | -127.28% |
| 2020 Q4 | -25.55 Million SEK | -36.93% |
| 2020 Q1 | 23 Thousand SEK | -99.29% |
| 2019 Q1 | -1.86 Million SEK | -119.12% |
| 2019 FY | - SEK | -11.74% |
| 2019 Q3 | 2.27 Million SEK | 18.04% |
| 2019 Q4 | 3.23 Million SEK | 41.9% |
| 2019 Q2 | 1.92 Million SEK | 203.6% |
| 2018 Q1 | 3.14 Million SEK | -39.36% |
| 2018 FY | - SEK | 53.52% |
| 2018 Q4 | 9.74 Million SEK | 1219.78% |
| 2018 Q3 | 738 Thousand SEK | -81.55% |
| 2018 Q2 | 3.99 Million SEK | 26.99% |
| 2017 Q2 | 1.96 Million SEK | 15015.38% |
| 2017 Q1 | 13 Thousand SEK | -96.63% |
| 2017 FY | - SEK | 37.96% |
| 2017 Q4 | 5.19 Million SEK | 1234.96% |
| 2017 Q3 | 389 Thousand SEK | -80.2% |
| 2016 Q2 | 1.66 Million SEK | -6.31% |
| 2016 Q1 | 1.77 Million SEK | -62.06% |
| 2016 FY | - SEK | -14.76% |
| 2016 Q4 | 386 Thousand SEK | 152.73% |
| 2016 Q3 | -732 Thousand SEK | -143.99% |
| 2015 Q2 | 1.49 Million SEK | 10086.67% |
| 2015 Q1 | -15 Thousand SEK | -102.91% |
| 2015 FY | - SEK | 64.53% |
| 2015 Q4 | 4.68 Million SEK | 250.9% |
| 2015 Q3 | 1.33 Million SEK | -10.95% |
| 2014 FY | - SEK | -5.08% |
| 2014 Q4 | 516 Thousand SEK | -77.2% |
| 2014 Q2 | 1.38 Million SEK | -49.31% |
| 2014 Q1 | 2.73 Million SEK | 2.01% |
| 2014 Q3 | 2.26 Million SEK | 63.04% |
| 2013 Q4 | 2.68 Million SEK | -0.3% |
| 2013 Q2 | 2 Million SEK | -42.14% |
| 2013 FY | - SEK | 5680.19% |
| 2013 Q1 | 3.46 Million SEK | 333.29% |
| 2013 Q3 | 2.69 Million SEK | 34.4% |
| 2012 Q4 | 799 Thousand SEK | 0.0% |
| 2012 FY | - SEK | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Acarix AB (publ) | -77.12 Million SEK | 264.122% |
| ADDvise Group AB (publ) | 411.9 Million SEK | 69.271% |
| ADDvise Group AB (publ) | 411.9 Million SEK | 69.271% |
| Arcoma AB | 6.24 Million SEK | -1925.832% |
| Bactiguard Holding AB (publ) | -89.98 Million SEK | 240.666% |
| BICO Group AB (publ) | 322.3 Million SEK | 60.728% |
| Boule Diagnostics AB (publ) | 65.97 Million SEK | -91.84% |
| CellaVision AB (publ) | 207.24 Million SEK | 38.925% |
| Clinical Laserthermia Systems AB (publ) | -68.4 Million SEK | 285.033% |
| Chordate Medical Holding AB (publ) | -27.94 Million SEK | 552.972% |
| C-Rad AB (publ) | 48.9 Million SEK | -158.821% |
| Duearity AB (publ) | -24.77 Million SEK | 610.812% |
| Dignitana AB (publ) | -264 Thousand SEK | 48044.697% |
| Episurf Medical AB (publ) | -87.7 Million SEK | 244.326% |
| Getinge AB (publ) | 5.92 Billion SEK | 97.865% |
| Scandinavian Real Heart AB (Publ) | -67.25 Million SEK | 288.214% |
| Iconovo AB (publ) | -35.33 Million SEK | 458.207% |
| Integrum AB (publ) | 8.76 Million SEK | -1344.657% |
| Luxbright AB (publ) | -23.86 Million SEK | 630.336% |
| Mentice AB (publ) | 28.87 Million SEK | -338.382% |
| OssDsign AB (publ) | -122.02 Million SEK | 203.731% |
| Paxman AB (publ) | 31.22 Million SEK | -305.309% |
| Promimic AB (publ) | -3.68 Million SEK | 3535.777% |
| Qlife Holding AB (publ) | -150.5 Million SEK | 184.1% |
| SciBase Holding AB (publ) | -51.82 Million SEK | 344.215% |
| ScandiDos AB (publ) | -13.35 Million SEK | 1047.694% |
| Sectra AB (publ) | 615.06 Million SEK | 79.421% |
| Sedana Medical AB (publ) | -51.67 Million SEK | 344.947% |
| Senzime AB (publ) | -118.82 Million SEK | 206.523% |
| SpectraCure AB (publ) | -20.96 Million SEK | 703.624% |
| Stille AB | 56.04 Million SEK | -125.86% |
| Vitrolife AB (publ) | -3.18 Billion SEK | 103.974% |